- $7.69m
- $21.54m
- $8.51m
- 38
- 40
- 57
- 41
Annual income statement for Evogene, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.04 | 0.93 | 1.68 | 5.64 | 8.51 |
| Cost of Revenue | |||||
| Gross Profit | 0.466 | -5.55 | -4.75 | -2.4 | 1.68 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 25.9 | 31.9 | 32.1 | 32.1 | 30.2 |
| Operating Profit | -24.8 | -31 | -30.4 | -26.5 | -21.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.2 | -30.4 | -29.8 | -26 | -18 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.2 | -30.4 | -29.8 | -26 | -18.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -23.4 | -27.8 | -26.6 | -23.9 | -16.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.4 | -27.8 | -26.6 | -23.9 | -16.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -8.3 | -6.86 | -6.45 | -5.23 | -2.89 |
| Dividends per Share |